EnteroMedics' Maestro "on track" despite FDA questions
This article was originally published in Clinica
Executive Summary
EnteroMedics has been hit by more potential problems with its Maestro neuromodulation-based weight-loss device – this time in the shape of questions from the US FDA in response to the firm’s premarket approval (PMA) application. The company’s share price fell 12% to a low of $1.07 during trading on 24 September, when the news was released, but ended up recovering to close down 2% at $1.18.